← Compound index
COMPOUND RECORD / CHITOMUR

ChitomurЧитомур

A peptide mixture extracted from animal bladder wall, studied in institute reports on urinary symptoms.

Source linked

What the studies found

Randomized study in people · 2013

Oral Chitomur versus capsule placebo in men with benign prostatic hyperplasia

Peak urinary flow · post-course
12.7 vs 9.4 mL/sChitomur versus placebo. One month later, 10.36 vs 8.3 mL/s.Table 1 marks p < 0.001 versus placebo at the post-course visit only.
Post-void residual urine · post-course
23.2 vs 72.1 mLOne month later, 48.7 vs 69.8 mL.Table 1 marks p < 0.001 versus placebo at both times.
International Prostate Symptom Score · post-course
13.2 vs 15.6 pointsOne month later, 15.7 vs 17.9. The table gives a single 17.4-point baseline.Table 2 marks p < 0.001 versus placebo at the post-course visit only.

Post-course peak urinary flow was 12.7 vs 9.4 mL/s and prostate symptom scores were 13.2 vs 15.6 with Chitomur versus placebo. Prostate volume showed no significant change.

More reported outcomes
Prostate volume and mean flow
No significant prostate-volume changeThe table gives no significance marker for mean urinary flow.
Adverse events
None reported among Chitomur recipientsThe paper gives no systematic harms table.
Study notes · methods, sources and limitations

Participants or model 50 men aged 62–83 with benign prostatic hyperplasia. Chitomur 30, capsule placebo 20.

Design Chitomur 30 versus capsule placebo 20. Uroflowmetry, post-void residual volume, prostate ultrasound, and IPSS and quality-of-life questionnaires.

Important limitations

  • Methods describe a blinded randomized study and the conclusion calls it open. The accessible report does not explain concealment, masking or placebo contents. Tables use a single baseline column and the reported endpoint timing varies. The sample and follow-up are too limited to characterize uncommon harms.
  • The small study reported differences in urinary symptoms and function; prostate size did not measurably change. The conflict about masking limits confidence.

Advances in Gerontology / Uspekhi Gerontologii. 2013;26(3):476–480. PMID 24640697. · Journal article — commercial reproduction

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗

Randomized study in people · 2013

Oral Chitomur versus usual treatment in women with overactive bladder

Urgency episodes · around day 15
4.05 → 2.83 vs 4.62 → 3.11Chitomur versus usual care, each compared with its own baseline. Later values 3.26 and 2.67.
Incontinence episodes · around day 15
1.34 → 0.83 vs 1.62 → 0.77Later values 0.91 and 0.61. Tables give within-group tests.
ICIQ-LUTS symptom score · around day 15
8.75 → 6.63 vs 8.25 → 5.72Later values 7.23 and 4.60.

Urgency episodes fell from 4.05 to 2.83 with Chitomur and from 4.62 to 3.11 with usual care around day 15. Later counts were 3.26 and 2.67, respectively.

More reported outcomes
Reported adverse events
0/30 vs 7/20Usual-care events included dry mouth and constipation. The drugs and ascertainment protocol are unspecified.
Study notes · methods, sources and limitations

Participants or model 50 women aged 48–80 with overactive bladder. Chitomur 30, usual care 20.

Design Chitomur 30 versus usual care 20. Bladder diaries and validated symptom questionnaires at baseline and around 15 and 45 days from treatment start.

Important limitations

  • The reproduction describes blinded random allocation without explaining concealment or how masking worked. Comparator drug schedules are unspecified. Tables compare each group with its own baseline. Baseline symptom counts differ. The report does not establish noninferiority or superior symptom control.
  • Symptoms improved in both groups. The later diary means favor usual care numerically on these measures. The report does not provide a formal noninferiority comparison.

Advances in Gerontology / Uspekhi Gerontologii. 2013;26(2):309–314. PMID 28976156. · Journal article — commercial reproduction

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗
01 / OVERVIEW

About Chitomur

Identity / background source ↗

Research background

Institute reports describe adjunctive Chitomur in people with urinary symptoms, including a comparison in women with overactive bladder. Background treatment and outcome reporting limit attribution.

Compound class
Archival preparation lead
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Two 50-person oral studies: placebo comparison for prostate symptoms and usual-care comparison for overactive bladder.

Study methods

The Russian reports describe 30 participants receiving Chitomur and 20 controls in each study. Masking and between-group comparisons have reporting limitations.

Independent replication

New citations are not automatically independent replication; shared programs and translated reports require cohort checks

Source access

Indexed abstracts and Russian full-article reproductions with methods and tables.

Safety evidence

Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

Russian article reproductions supply methods and numerical tables for both 50-person studies. The men’s paper gives conflicting masking descriptions and post-course timing. In the women’s report, the exact usual-care regimen and formal between-group tests remain unclear.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Randomized study in people · 2013

Oral Chitomur versus usual treatment in women with overactive bladder

Urgency episodes fell from 4.05 to 2.83 with Chitomur and from 4.62 to 3.11 with usual care around day 15. Later counts were 3.26 and 2.67, respectively.

Study notes and original source
2013Randomized trialFull text available

Oral Chitomur versus usual treatment in women with overactive bladder

Oral bladder tissue peptide preparation. · Journal article — commercial reproduction

V. G. Gomberg, A. P. Ryzhak, R. V. Lyutov · Advances in Gerontology / Uspekhi Gerontologii. 2013;26(2):309–314. PMID 28976156.

Urgency episodes fell from 4.05 to 2.83 with Chitomur and from 4.62 to 3.11 with usual care around day 15. Later counts were 3.26 and 2.67, respectively.

Results and tables

Reported findings and study design

Chitomur 30 versus usual care 20. Bladder diaries and validated symptom questionnaires at baseline and around 15 and 45 days from treatment start.

Population or model 50 women aged 48–80 with overactive bladder. Chitomur 30, usual care 20.

Dose, route and schedule

Two capsules twice daily with meals for 15 days, beginning after a three-day bladder diary. Capsule peptide mass is unspecified in this paper. The comparator received usual treatment. The discussion identifies muscarinic antagonists but gives no drug or dose.

Protocol source ↗ · Russian full-article reproduction, methods and Tables 1 and 3–6. Indexed abstract cross-checked.

Results · Russian full-article reproduction, methods and Tables 1 and 3–6. Indexed abstract cross-checked.
MeasureResultComparison, timing and statistics
Urgency episodes · around day 154.05 → 2.83 vs 4.62 → 3.11Chitomur versus usual care, each compared with its own baseline. Later values 3.26 and 2.67.
Incontinence episodes · around day 151.34 → 0.83 vs 1.62 → 0.77Later values 0.91 and 0.61. Tables give within-group tests.
ICIQ-LUTS symptom score · around day 158.75 → 6.63 vs 8.25 → 5.72Later values 7.23 and 4.60.
Reported adverse events0/30 vs 7/20Usual-care events included dry mouth and constipation. The drugs and ascertainment protocol are unspecified.
Tables 1 and 4 · bladder diaries
Tables 1 and 4 · bladder diaries
MeasureChitomur baseline / early / laterUsual care baseline / early / later
Voids per day9.69 / 8.64 / 8.1210.17 / 8.85 / 7.62
Urgency episodes4.05 / 2.83 / 3.264.62 / 3.11 / 2.67
Incontinence episodes1.34 / 0.83 / 0.911.62 / 0.77 / 0.61
Nighttime voids2.10 / 1.51 / 1.692.32 / 1.67 / 1.53

Printed means. Early is about day 15. Later is one month after the Chitomur course or 1.5 months after usual care began. Significance markers compare each arm with its own baseline.

Symptoms improved in both groups. The later diary means favor usual care numerically on these measures. The report does not provide a formal noninferiority comparison.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
50 women aged 48–80 with overactive bladder. Chitomur 30, usual care 20.
Source reviewed
Russian full-article reproduction, methods and Tables 1 and 3–6. Indexed abstract cross-checked.
Study limitations
  • The reproduction describes blinded random allocation without explaining concealment or how masking worked. Comparator drug schedules are unspecified.
  • Tables compare each group with its own baseline. Baseline symptom counts differ. The report does not establish noninferiority or superior symptom control.

Reviewed 2026-11-14.

Read the source ↗

Randomized study in people · 2013

Oral Chitomur versus capsule placebo in men with benign prostatic hyperplasia

Post-course peak urinary flow was 12.7 vs 9.4 mL/s and prostate symptom scores were 13.2 vs 15.6 with Chitomur versus placebo. Prostate volume showed no significant change.

Study notes and original source
2013Randomized trialFull text available

Oral Chitomur versus capsule placebo in men with benign prostatic hyperplasia

Oral calf bladder-derived peptide preparation. · Journal article — commercial reproduction

V. G. Gomberg, A. P. Ryzhak, R. V. Lyutov · Advances in Gerontology / Uspekhi Gerontologii. 2013;26(3):476–480. PMID 24640697.

Post-course peak urinary flow was 12.7 vs 9.4 mL/s and prostate symptom scores were 13.2 vs 15.6 with Chitomur versus placebo. Prostate volume showed no significant change.

Results and tables

Reported findings and study design

Chitomur 30 versus capsule placebo 20. Uroflowmetry, post-void residual volume, prostate ultrasound, and IPSS and quality-of-life questionnaires.

Population or model 50 men aged 62–83 with benign prostatic hyperplasia. Chitomur 30, capsule placebo 20.

Dose, route and schedule

Two 10 mg capsules twice daily with meals for 15 days (40 mg/day as reported). The comparator received placebo capsules. Methods place the post-course visit on day 16. The results narrative also uses day 14.

Protocol source ↗ · Russian full-article reproduction, methods and Tables 1–2. Indexed citation and abstract cross-checked. The indexed second-author initials differ from the reproduction.

Results · Russian full-article reproduction, methods and Tables 1–2. Indexed citation and abstract cross-checked. The indexed second-author initials differ from the reproduction.
MeasureResultComparison, timing and statistics
Peak urinary flow · post-course12.7 vs 9.4 mL/sChitomur versus placebo. One month later, 10.36 vs 8.3 mL/s. · Table 1 marks p < 0.001 versus placebo at the post-course visit only.
Post-void residual urine · post-course23.2 vs 72.1 mLOne month later, 48.7 vs 69.8 mL. · Table 1 marks p < 0.001 versus placebo at both times.
International Prostate Symptom Score · post-course13.2 vs 15.6 pointsOne month later, 15.7 vs 17.9. The table gives a single 17.4-point baseline. · Table 2 marks p < 0.001 versus placebo at the post-course visit only.
Prostate volume and mean flowNo significant prostate-volume changeThe table gives no significance marker for mean urinary flow.
Adverse eventsNone reported among Chitomur recipientsThe paper gives no systematic harms table.
Tables 1–2 · urinary measures by visit
Tables 1–2 · urinary measures by visit
MeasureSingle baseline columnChitomur post-coursePlacebo post-courseChitomur one month laterPlacebo one month later
Peak flow (mL/s)8.9 ± 0.812.7 ± 0.89.4 ± 1.410.36 ± 0.98.3 ± 1.7
Mean flow (mL/s)4.1 ± 0.74.7 ± 1.34.2 ± 1.64.4 ± 1.53.9 ± 1.7
Residual urine (mL)77.4 ± 16.123.2 ± 8.972.1 ± 19.248.7 ± 10.569.8 ± 13.7
IPSS17.4 ± 0.913.2 ± 1.215.6 ± 2.215.7 ± 1.117.9 ± 3.1
Quality-of-life index3.3 ± 0.22.4 ± 0.32.9 ± 0.52.8 ± 0.33.2 ± 0.6

Printed means and ± terms. The report gives one baseline column and inconsistent post-course timing. Peak flow and IPSS moved back toward baseline at follow-up.

The small study reported differences in urinary symptoms and function; prostate size did not measurably change. The conflict about masking limits confidence.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
50 men aged 62–83 with benign prostatic hyperplasia. Chitomur 30, capsule placebo 20.
Source reviewed
Russian full-article reproduction, methods and Tables 1–2. Indexed citation and abstract cross-checked. The indexed second-author initials differ from the reproduction.
Study limitations
  • Methods describe a blinded randomized study and the conclusion calls it open. The accessible report does not explain concealment, masking or placebo contents.
  • Tables use a single baseline column and the reported endpoint timing varies. The sample and follow-up are too limited to characterize uncommon harms.

Reviewed 2026-11-14.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗